3 Stocks That Already Doubled in 2023 and Could Keep Climbing
Are you looking for stocks that can deliver big gains in a short amount of time? If so, you may have already noticed these three life science industry stocks have already doubled since the beginning of the year.
The first few months of 2023 have been outstanding for these stocks and there's a chance they could climb even higher before the year's finished. There are always a lot of ins and outs when it comes to developing and selling new treatments. Read on to find out why these stocks jumped and how they could do it again.
Shares of Reata Pharmaceuticals (NASDAQ: RETA) are up 147% this year following a huge spike on Feb. 28. That's when the U.S. Food and Drug Administration (FDA) granted approval to the company's first drug. Skyclarys is the first and only drug approved to treat an ultra-rare neuromuscular disorder called Friedreich's ataxia.
Source Fool.com
